Royalty Net Income vs Operating Income Analysis
RPRX Stock | USD 27.41 1.02 3.87% |
Royalty PharmaPlc financial indicator trend analysis is much more than just breaking down Royalty PharmaPlc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Royalty PharmaPlc is a good investment. Please check the relationship between Royalty PharmaPlc Net Income and its Operating Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty PharmaPlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Royalty Stock please use our How to Invest in Royalty PharmaPlc guide.
Net Income vs Operating Income
Net Income vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Royalty PharmaPlc Net Income account and Operating Income. At this time, the significance of the direction appears to have very strong relationship.
The correlation between Royalty PharmaPlc's Net Income and Operating Income is 0.87. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Operating Income in the same time period over historical financial statements of Royalty PharmaPlc, assuming nothing else is changed. The correlation between historical values of Royalty PharmaPlc's Net Income and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Royalty PharmaPlc are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Net Income i.e., Royalty PharmaPlc's Net Income and Operating Income go up and down completely randomly.
Correlation Coefficient | 0.87 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Royalty PharmaPlc financial statement analysis. It represents the amount of money remaining after all of Royalty PharmaPlc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Operating Income
Operating Income is the amount of profit realized from Royalty PharmaPlc operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Royalty PharmaPlc is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from Royalty PharmaPlc's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Royalty PharmaPlc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty PharmaPlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Royalty Stock please use our How to Invest in Royalty PharmaPlc guide.At this time, Royalty PharmaPlc's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to 0.00 in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.06 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 51.4M | 5.7M | 5.1M | 4.8M | Interest Income | 53.5M | 78.3M | 72.3M | 45.0M |
Royalty PharmaPlc fundamental ratios Correlations
Click cells to compare fundamentals
Royalty PharmaPlc Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Royalty PharmaPlc fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 12.4B | 21.1B | 17.5B | 16.8B | 16.4B | 17.2B | |
Other Current Liab | 9.2M | 297.1M | 165.6M | 161.4M | 146.2M | 153.5M | |
Total Current Liabilities | 333.4M | 307.9M | 171.3M | 1.2B | 161.4M | 132.4M | |
Total Stockholder Equity | 6.1B | 9.9B | 5.8B | 5.6B | 6.5B | 6.9B | |
Accounts Payable | 11.2M | 10.8M | 5.6M | 7.9M | 15.2M | 15.9M | |
Cash | 283.7M | 1.0B | 1.5B | 1.7B | 477.0M | 343.9M | |
Other Assets | 10.9B | 5.1B | 13.7B | 13.5B | 15.5B | 16.3B | |
Common Stock Shares Outstanding | 365.9M | 375.5M | 414.8M | 438.0M | 602.9M | 409.1M | |
Short Term Investments | 509.5M | 983M | 1.3B | 717.0M | 18.3M | 17.4M | |
Other Current Assets | 92K | 8.6M | 6.6M | 90.5M | 3.8M | 5.8M | |
Total Liab | 6.3B | 6.1B | 7.3B | 7.3B | 6.3B | 6.6B | |
Intangible Assets | 51.7M | 28.7M | 5.7M | 14.5M | 1.8M | 1.7M | |
Net Tangible Assets | 6.1B | 4.8B | 5.8B | 5.6B | 6.5B | 3.7B | |
Retained Earnings | 2.8B | 1.9B | 2.3B | 2.0B | 2.5B | 1.4B | |
Total Current Assets | 832.1M | 2.7B | 2.9B | 2.6B | 1.3B | 1.6B | |
Short Long Term Debt Total | 6.2B | 5.8B | 7.1B | 7.1B | 6.1B | 7.1B | |
Net Debt | 6.0B | 4.8B | 5.6B | 5.4B | 5.7B | 5.9B | |
Non Current Assets Total | 11.6B | 13.3B | 14.6B | 14.3B | 15.1B | 14.2B | |
Non Currrent Assets Other | 88.0M | 28.6M | 4.1M | 15.1M | 14.1B | 14.8B | |
Long Term Debt | 6.0B | 5.8B | 7.1B | 6.1B | 6.1B | 6.8B | |
Cash And Short Term Investments | 793.2M | 2.0B | 2.8B | 2.4B | 495.3M | 470.5M | |
Net Receivables | 38.8M | 39.2M | 68.3M | 36.6M | 775.1M | 813.8M | |
Long Term Debt Total | 6.0B | 5.8B | 7.1B | 6.1B | 7.0B | 6.9B | |
Liabilities And Stockholders Equity | 12.4B | 21.1B | 17.5B | 16.8B | 16.4B | 17.5B | |
Non Current Liabilities Total | 6.0B | 5.8B | 7.1B | 6.1B | 6.1B | 6.9B | |
Other Stockholder Equity | (4.3M) | 7.9B | 3.5B | 3.7B | 4.0B | 3.5B | |
Net Invested Capital | 12.3B | 10.6B | 12.9B | 12.7B | 12.7B | 13.2B | |
Long Term Investments | 11.5B | 13.0B | 14.4B | 14.1B | 15.1B | 14.1B | |
Accumulated Other Comprehensive Income | 2.1M | 34.4M | 16.5M | 63K | 72.5K | 68.8K | |
Net Working Capital | 498.7M | 2.4B | 2.7B | 1.4B | 1.1B | 1.3B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Royalty PharmaPlc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Royalty PharmaPlc's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Royalty Pharmaplc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Royalty Pharmaplc Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty PharmaPlc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Royalty Stock please use our How to Invest in Royalty PharmaPlc guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Royalty Stock analysis
When running Royalty PharmaPlc's price analysis, check to measure Royalty PharmaPlc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty PharmaPlc is operating at the current time. Most of Royalty PharmaPlc's value examination focuses on studying past and present price action to predict the probability of Royalty PharmaPlc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty PharmaPlc's price. Additionally, you may evaluate how the addition of Royalty PharmaPlc to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Royalty PharmaPlc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Royalty PharmaPlc. If investors know Royalty will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Royalty PharmaPlc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Dividend Share 0.81 | Earnings Share 1.78 | Revenue Per Share 4.993 | Quarterly Revenue Growth (0.17) |
The market value of Royalty PharmaPlc is measured differently than its book value, which is the value of Royalty that is recorded on the company's balance sheet. Investors also form their own opinion of Royalty PharmaPlc's value that differs from its market value or its book value, called intrinsic value, which is Royalty PharmaPlc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Royalty PharmaPlc's market value can be influenced by many factors that don't directly affect Royalty PharmaPlc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Royalty PharmaPlc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Royalty PharmaPlc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Royalty PharmaPlc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.